Results 181 to 190 of about 26,349 (219)

Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy

Current Opinion in Cardiology, 2023
Purpose of review Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The objective of this review is to discuss the mechanisms of action, clinical trial evidence, safety profile and monitoring of CMIs, which are important to the ...
Safia, Chatur, Sheila M, Hegde
openaire   +2 more sources

Discovery of a novel cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy

Chinese Chemical Letters
Lihong Hu
exaly   +2 more sources

Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors

Journal of Cardiothoracic and Vascular Anesthesia
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias ...
Paul S, Pagel, Dustin, Hang, Julie K, Freed, George J, Crystal   +3 more
openaire   +2 more sources

The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy

Canadian Journal of Cardiology
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy worldwide and causes significant morbidity and mortality. For decades, medical treatment options have been limited and untargeted, with frequent need for invasive interventions not readily accessible to many HCM patients.
Rebecca Haraf, Hany Habib, Ahmad Masri
openaire   +2 more sources

Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy

Med
A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these
Milind Y, Desai, Eugene, Braunwald
openaire   +2 more sources

Heart of the matter: A GP’s guide to cardiac myosin inhibitors

InnovAiT: Education and inspiration for general practice
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition. It causes hypertrophy of the heart muscle and left ventricular outflow tract obstruction. Hypertrophic cardiomyopathy (HCM) is one of the most prevalent inherited cardiac disorders, with more than 1400 mutations discovered.
Naneishvili, Tamara; id_orcid 0000-0001-9577-7186, How, Wei Jun, Andrade, Ivo, Cummins, Samantha, Hutchings, David; id_orcid 0000-0002-5402-8565, Malhotra, Aneil, Venetucci, Luigi, Beynon, Rhys, Crean, Andrew; id_orcid 0000-0002-2038-9178   +8 more
openaire   +4 more sources

Recent trend in the therapy of hypertrophic cardiomyopathy: Cardiac myosin inhibitors

2023
Cardiac myosin inhibitors are a new class of drugs that have recently been approved in obstructive hypertrophic cardiomyopathy. The main mechanism of action is to reduce the pathologically increased cardiac hypercontractility. Current drug therapies have not been demonstrated to modify the natural progress of the disease.
DEMİRKIRAN, Cahit, DEMİRYÜREK, Şeniz, DEMİRYÜREK, Abdullah Tuncay   +2 more
openaire   +1 more source

Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology, 2022
openaire   +1 more source

FDA okays first cardiac myosin inhibitor

Nature Biotechnology, 2022
openaire   +1 more source

Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure, 2023
John W. Ostrominski, Ruby Guo, Perry M. Elliott, Carolyn Y. Ho   +3 more
openaire   +1 more source